This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cunningham, C. C. Articles by Nemunaitis, J. Search for Related Content PubMed PubMed Citation Articles by Cunningham, C. C. Articles by Nemunaitis, J.

A Phase I Trial of c-Raf Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer

US Oncology, Dallas, Texas 75246 [C. C. C., J. N.]; Baylor University Medical Center, Sammons Cancer Center, Dallas, Texas [C. C. C., J. N.]; ISIS Pharmaceuticals, Carlsbad, California [J. T. H., R. S. G., T. J. K., A. D.]; and University of Wisconsin, Madison, Wisconsin [J. H. S.]

Raf proteins play a central role in the mitogen-activated protein kinase signaling pathway and hence are involved in oncogenic transformation and tumor cell proliferation. ISIS 5132 is a 20-base antisense phosphorothioate oligodeoxyribonucleotide that specifically down-regulates c-raf expression. We report here an initial study of the safety and tolerability of an i.v. infusion of ISIS 5132 in patients with advanced cancer. A continuous i.v. infusion of ISIS 5132 was administered for 21 days every 4 weeks to 34 patients with a variety of solid tumors refractory to standard therapy. The dose of ISIS 5132 was increased in sequential cohorts of patients, as toxicity allowed, until a final dose of 5.0 mg/kg body weight was reached. Toxicity was scored by common toxicity criteria, and tumor response was monitored. Pharmacokinetic studies were performed for 30 patients treated at doses of 4.0 mg/kg/day. The initial dose of ISIS 5132 was 0.5 mg/kg body weight and was successfully increased incrementally to 5.0 mg/kg body weight. Toxicities through the 4.0 mg/kg dose level were not dose limiting. Side effects were minimal and could not be specifically related to ISIS 5132. Two patients had prolonged stabilization of their disease, and one patient with ovarian carcinoma had a significant response with a 97% reduction in CA-125 levels. ISIS 5132, an antisense oligonucleotide against c-raf, was well tolerated at doses up to and including 4.0 mg/kg/day by 21-day continuous i.v. infusion and demonstrated antitumor activity at the doses tested.

This article has been cited by other articles:

				D. A. Kocisko, A. Vaillant, K. S. Lee, K. M. Arnold, N. Bertholet, R. E. Race, E. A. Olsen, J.-M. Juteau, and B. Caughey Potent Antiscrapie Activities of Degenerate Phosphorothioate Oligonucleotides Antimicrob. Agents Chemother., March 1, 2006; 50(3): 1034 - 1044. [Abstract] [Full Text] [PDF]

				M. Beeram, A. Patnaik, and E. K. Rowinsky Raf: A Strategic Target for Therapeutic Development Against Cancer J. Clin. Oncol., September 20, 2005; 23(27): 6771 - 6790. [Abstract] [Full Text] [PDF]

				A. Hachem and R. B. Gartenhaus Oncogenes as molecular targets in lymphoma Blood, September 15, 2005; 106(6): 1911 - 1923. [Full Text] [PDF]

				M. Lowenberg, A. Verhaar, B. van den Blink, F. ten Kate, S. van Deventer, M. Peppelenbosch, and D. Hommes Specific Inhibition of c-Raf Activity by Semapimod Induces Clinical Remission in Severe Crohn's Disease J. Immunol., August 15, 2005; 175(4): 2293 - 2300. [Abstract] [Full Text] [PDF]

				W. R. Parulekar and E. A. Eisenhauer Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice J Natl Cancer Inst, July 7, 2004; 96(13): 990 - 997. [Abstract] [Full Text] [PDF]

				P. Mullen, F. McPhillips, K. MacLeod, B. Monia, J. F. Smyth, and S. P. Langdon Antisense Oligonucleotide Targeting of Raf-1: Importance of Raf-1 mRNA Expression Levels and Raf-1-Dependent Signaling in Determining Growth Response in Ovarian Cancer Clin. Cancer Res., March 15, 2004; 10(6): 2100 - 2108. [Abstract] [Full Text] [PDF]

				R. S. Geary, R. Z. Yu, T. Watanabe, S. P. Henry, G. E. Hardee, A. Chappell, J. Matson, H. Sasmor, L. Cummins, and A. A. Levin PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-{alpha} PHOSPHOROTHIOATE 2'-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIES Drug Metab. Dispos., November 1, 2003; 31(11): 1419 - 1428. [Abstract] [Full Text] [PDF]

				J. B. Opalinska and A. M. Gewirtz Therapeutic Potential of Antisense Nucleic Acid Molecules Sci. Signal., October 28, 2003; 2003(206): pe47 - pe47. [Abstract] [Full Text] [PDF]

				C. A. Burkhart, A. J. Cheng, J. Madafiglio, M. Kavallaris, M. Mili, G. M. Marshall, W. A. Weiss, L. M. Khachigian, M. D. Norris, and M. Haber Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma J Natl Cancer Inst, September 17, 2003; 95(18): 1394 - 1403. [Abstract] [Full Text] [PDF]

				M. Braga-Basaria and M. D. Ringel Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1947 - 1960. [Abstract] [Full Text] [PDF]

				A. A. Adjei, G. K. Dy, C. Erlichman, J. M. Reid, J. A. Sloan, H. C. Pitot, S. R. Alberts, R. M. Goldberg, L. J. Hanson, P. J. Atherton, et al. A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Gemcitabine in Patients with Advanced Cancer Clin. Cancer Res., January 1, 2003; 9(1): 115 - 123. [Abstract] [Full Text] [PDF]

				B. Boettner and L. Van Aelst The RASputin effect Genes & Dev., August 15, 2002; 16(16): 2033 - 2038. [Full Text] [PDF]

				N. M. Hamad, J. H. Elconin, A. E. Karnoub, W. Bai, J. N. Rich, R. T. Abraham, C. J. Der, and C. M. Counter Distinct requirements for Ras oncogenesis in human versus mouse cells Genes & Dev., August 15, 2002; 16(16): 2045 - 2057. [Abstract] [Full Text] [PDF]

				Q. Hu, M. B. Bally, and T. D. Madden Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system Nucleic Acids Res., August 1, 2002; 30(16): 3632 - 3641. [Abstract] [Full Text] [PDF]

				A. W. Tolcher, L. Reyno, P. M. Venner, S. D. Ernst, M. Moore, R. S. Geary, K. Chi, S. Hall, W. Walsh, A. Dorr, et al. A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer Clin. Cancer Res., August 1, 2002; 8(8): 2530 - 2535. [Abstract] [Full Text] [PDF]

				C. G. Ferreira, M. Epping, F. A. E. Kruyt, and G. Giaccone Apoptosis: Target of Cancer Therapy Clin. Cancer Res., July 1, 2002; 8(7): 2024 - 2034. [Abstract] [Full Text] [PDF]

				M. C. Cripps, A. T. Figueredo, A. M. Oza, M. J. Taylor, A. L. Fields, J. T. Holmlund, L. W. McIntosh, R. S. Geary, and E. A. Eisenhauer Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Locally Advanced or Metastatic Colorectal Cancer: A National Cancer Institute of Canada Clinical Trials Group Study Clin. Cancer Res., July 1, 2002; 8(7): 2188 - 2192. [Abstract] [Full Text] [PDF]

				G. K. Dy and A. A. Adjei Novel Targets for Lung Cancer Therapy: Part I J. Clin. Oncol., June 15, 2002; 20(12): 2881 - 2894. [Abstract] [Full Text] [PDF]

				R. P. Singh, A. K. Tyagi, J. Zhao, and R. Agarwal Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis Carcinogenesis, March 1, 2002; 23(3): 499 - 510. [Abstract] [Full Text] [PDF]

				S. M. Luger, S. G. O'Brien, J. Ratajczak, M. Z. Ratajczak, R. Mick, E. A. Stadtmauer, P. C. Nowell, J. M. Goldman, and A. M. Gewirtz Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study Blood, February 15, 2002; 99(4): 1150 - 1158. [Abstract] [Full Text] [PDF]

				C. M. Rudin, J. Holmlund, G. F. Fleming, S. Mani, W. M. Stadler, P. Schumm, B. P. Monia, J. F. Johnston, R. Geary, R. Z. Yu, et al. Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of c-raf-1, Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1214 - 1220. [Abstract] [Full Text]

				F. R. Khuri and J. M. Kurie Antisense Approaches Enter the Clinic Clin. Cancer Res., May 1, 2000; 6(5): 1607 - 1610. [Full Text]